The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction

Kuźma, Łukasz; Kulikowska, Agata; Kurasz, Anna; Niwińska, Marta Maria; Zalewska-Adamiec, Małgorzata; Dobrzycki, Sławomir; Bachórzewska−Gajewska, Hanna

doi:10.17219/acem/127145

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have demonstrated that hyperuricemia is associated with the development of adverse cardiovascular events in patients with CAD although the degree of this association may vary between different genders and geographies [ 8 , 33 , 34 ]. Clinically, CAD can be divided into two major categories, including acute coronary syndrome (ACS) and stable CAD [ 35 ].…”

Section: The Correlation Between Hyperuricemia and Cadmentioning

confidence: 99%

“…Moreover, a prospective study conducted in Austria showed that hyperuricemia was not associated with mortality in acute, subacute or chronic CAD [ 34 ]. In contrast, in a Polish study that evaluated the relationship between uric acid levels and its long-term prognosis in patients with NSTEMI, the authors retrospectively analyzed the association of uric acid in 549 patients hospitalized with NSTEMI and showed that uric acid was an independent risk factor for NSTEMI [ 8 ].…”

Section: The Correlation Between Hyperuricemia and Cadmentioning

confidence: 99%

“…In addition, by comparing the mortality rates of those followed up to 6 years, they found that the percentage of patients with hyperuricemia was nearly doubled compared with patients with normal uric acid, leading to a conclusion that hyperuricemia is associated with long-term mortality in NSTEMI [ 8 ]. A Meta analysis also showed that patients with STEMI in the presence of hyperuricemia had a significantly higher incidence of in-hospital cardiovascular events, in-hospital mortality, and 1-year post-discharge mortality than the STEMI population with normal uric acid concentrations [ 37 ].…”

Section: The Correlation Between Hyperuricemia and Cadmentioning

confidence: 99%

“…Comparing to the known causative factors such as lipids and glucose in CAD prevention, little attention and investigation have been put on hyperuricemia in cardiovascular diseases [ 4 ]. Although some studies question the independent risk role of uric acid and more studies suggest that hyperuricemia has a negative impact on the onset, progression and prognosis of CAD [ [5] , [6] , [7] , [8] ]. There is also evidence that hyperuricemia is inextricably linked to traditional risk factors for CAD, which may have jointly contributed to the onset and development of CAD [ [9] , [10] , [11] ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor

Yao

Shui

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: The Correlation Between Hyperuricemia and Cadmentioning

confidence: 99%

Section: The Correlation Between Hyperuricemia and Cadmentioning

confidence: 99%

Section: The Correlation Between Hyperuricemia and Cadmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor

Yao

Shui

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…In patients with MI, hyperuricemia is nowadays an established risk factor for adverse cardiovascular events, including cardiovascular mortality, independent of the presence of metabolic syndrome [ 41 ]. Among 549 patients with acute MI without ST elevation, increased SUA levels were associated with a 1.5-fold higher risk of mortality and with increased in-hospital death rates when compared to normouricemic patients [ 42 ], and it seems that the addition of SUA to the GRACE score results in a better prediction of in-hospital mortality among patients with acute coronary syndrome [ 43 ]. Furthermore, among 1005 patients with acute MI treated with percutaneous coronary intervention (PCI), preprocedural hyperuricemia was independently associated with increased long-term mortality rates [ 44 ].…”

Section: Uric Acid As a Risk Marker For Thrombosis In Different Clinical Scenariosmentioning

confidence: 99%

Uric Acid—An Emergent Risk Marker for Thrombosis?

Țăpoi¹,

Șalaru

Sascău

et al. 2021

JCM

View full text Add to dashboard Cite

Hyperuricemia is nowadays an established cardiovascular risk factor. Experimental studies linked elevated serum uric acid (SUA) levels with endothelial dysfunction (ED), inflammation, and prothrombotic state. The purpose of this review is to summarize the current evidence that emphasizes the possible role of uric acid as a biomarker for a prothrombotic state. A large number of clinical trials correlated SUA levels with both incident and recurrent cases of venous thromboembolism (VTE), independent of other confounding risk factors. Moreover, increased SUA levels may be an important tool for the risk stratification of patients with pulmonary embolism (PE). Left atrial thrombosis was correlated with high SUA levels in several studies and its addition to classical risk scores improved their predictive abilities. In patients with acute myocardial infarction (MI), hyperuricemia was associated with increased mortality, and the idea that hyperuricemia may be able to act as a surrogate to unstable coronary plaques was advanced. Finally, SUA was correlated with an increased risk of thromboembolic events in different systemic diseases. In conclusion, uric acid has been considered a marker of a thrombotic milieu in several clinical scenarios. However, this causality is still controversial, and more experimental and clinical data is needed.

show abstract

Association of serum uric acid with prognosis in patients with myocardial infarction: an update systematic review and meta-analysis

Rong,

Fang,

Chen

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background The prognostic significance of serum uric acid (SUA) in individuals who have experienced myocardial infarction (MI) remains a subject of academic debate. Thus, the aim of this study was to examine the occurrence of immediate and long-term adverse outcomes in individuals with elevated levels of uric acid (UA) following a diagnosis of MI. Method This study conducted a literature search from PubMed, Embase, Web of Science, Medline, Cochrane Library, Emcrae, and Scopus to perform a systematic review and meta-analysis of the prognostic impact of MI with a hyper SUA to assess short-term (30-day or in-hospital) and long-term mortality, the incidence of major adverse cardiovascular events (MACE), and its adverse event rate in relation to SUA. The literature search was conducted up until April 2023. A random effects model and risk ratio (RR) were used as epidemiological indicators. For indicators with low disease rates, treatment intensity was reduced and RR was considered equivalent to odds ratio (OR). Hazard Ratio (HR), RR, and OR extracted from the data were simultaneously subjected to multivariable adjustment for confounding factors. In addition, P values for all original hypotheses were extracted and a meta-analysis was conducted. High SUA was defined as SUA levels equal to or greater than 420 μmol/L (7.0 mg/dL) for males and equal to or greater than 357 μmol/L (6.0 mg/dL) for females. The quality of the literature was evaluated using the Newcastle–Ottawa Scale (NOS). Results This comprehensive study included a total of 41 investigations, involving a large sample size of 225,600 individuals who had experienced MI. The findings from the meta-analysis reveal that patients diagnosed with hyperuricemia have significantly increased rates of short-term mortality (RR = 2.14, 95% CI = 1.86, 2.48) and short-term incidence of MACE (RR = 1.94, 95% CI = 1.65–2.11). Furthermore, long-term adverse outcomes, including all-cause mortality (RR = 1.46, 95% CI = 1.40–1.51) and incidence of MACE (RR = 1.43, 95% CI = 1.35–1.52), were also found to be higher in this specific patient population. Conclusion Patients diagnosed with MI and elevated SUA levels exhibit a heightened incidence of MACE during their hospital stay. Furthermore, these individuals also experience elevated rates of in-hospital mortality and mortality within one year of hospitalization. However, it is important to note that further randomized controlled trials are necessary to validate and authenticate these findings.

show abstract

The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction

Cited by 6 publications

References 0 publications

The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor

The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor

Uric Acid—An Emergent Risk Marker for Thrombosis?

Association of serum uric acid with prognosis in patients with myocardial infarction: an update systematic review and meta-analysis

Contact Info

Product

Resources

About